# Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes

> **NCT00398047** · PHASE2 · TERMINATED · sponsor: **Wake Forest University Health Sciences** · enrollment: 3 (actual)

## Conditions studied

- Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Azacitadine and Hematopoietic Growth Factors

## Key facts

- **NCT ID:** NCT00398047
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-09
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2018-09-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00398047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00398047, "Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00398047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*